These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 21605898)

  • 21. Gene silencing via RNAi and siRNA quantification in tumor tissue using MEND, a liposomal siRNA delivery system.
    Sakurai Y; Hatakeyama H; Sato Y; Hyodo M; Akita H; Harashima H
    Mol Ther; 2013 Jun; 21(6):1195-203. PubMed ID: 23568259
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lipid-based nanoparticles for siRNA delivery in cancer therapy: paradigms and challenges.
    Gomes-da-Silva LC; Fonseca NA; Moura V; Pedroso de Lima MC; Simões S; Moreira JN
    Acc Chem Res; 2012 Jul; 45(7):1163-71. PubMed ID: 22568781
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Stearylated INF7 peptide enhances endosomal escape and gene expression of PEGylated nanoparticles both in vitro and in vivo.
    El-Sayed A; Masuda T; Akita H; Harashima H
    J Pharm Sci; 2012 Feb; 101(2):879-82. PubMed ID: 22086751
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Failure of active targeting by a cholesterol-anchored ligand and improvement by altering the lipid composition to prevent ligand desorption.
    Yamamoto S; Sakurai Y; Harashima H
    Int J Pharm; 2018 Jan; 536(1):42-49. PubMed ID: 29126905
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fusogenic peptides enhance endosomal escape improving siRNA-induced silencing of oncogenes.
    Oliveira S; van Rooy I; Kranenburg O; Storm G; Schiffelers RM
    Int J Pharm; 2007 Mar; 331(2):211-4. PubMed ID: 17187949
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A peptide-targeted delivery system with pH-sensitive amphiphilic cell membrane disruption for efficient receptor-mediated siRNA delivery.
    Wang XL; Xu R; Lu ZR
    J Control Release; 2009 Mar; 134(3):207-13. PubMed ID: 19135104
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cytoplasm-responsive nanocarriers conjugated with a functional cell-penetrating peptide for systemic siRNA delivery.
    Tanaka K; Kanazawa T; Horiuchi S; Ando T; Sugawara K; Takashima Y; Seta Y; Okada H
    Int J Pharm; 2013 Oct; 455(1-2):40-7. PubMed ID: 23911914
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficient short interference RNA delivery to tumor cells using a combination of octaarginine, GALA and tumor-specific, cleavable polyethylene glycol system.
    Sakurai Y; Hatakeyama H; Akita H; Oishi M; Nagasaki Y; Futaki S; Harashima H
    Biol Pharm Bull; 2009 May; 32(5):928-32. PubMed ID: 19420766
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Receptor-targeted liposome-peptide nanocomplexes for siRNA delivery.
    Tagalakis AD; He L; Saraiva L; Gustafsson KT; Hart SL
    Biomaterials; 2011 Sep; 32(26):6302-15. PubMed ID: 21624650
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Improvement of doxorubicin efficacy using liposomal anti-polo-like kinase 1 siRNA in human renal cell carcinomas.
    Sakurai Y; Hatakeyama H; Akita H; Harashima H
    Mol Pharm; 2014 Aug; 11(8):2713-9. PubMed ID: 24800640
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery.
    Landen CN; Chavez-Reyes A; Bucana C; Schmandt R; Deavers MT; Lopez-Berestein G; Sood AK
    Cancer Res; 2005 Aug; 65(15):6910-8. PubMed ID: 16061675
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enhanced siRNA delivery using cationic liposomes with new polyarginine-conjugated PEG-lipid.
    Kim HK; Davaa E; Myung CS; Park JS
    Int J Pharm; 2010 Jun; 392(1-2):141-7. PubMed ID: 20347025
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Development of an efficient short interference RNA (siRNA) delivery system with a new pH-sensitive cationic lipid].
    Sato Y; Hatakeyama H; Hyodo M; Akita H; Harashima H
    Yakugaku Zasshi; 2012; 132(12):1355-63. PubMed ID: 23208041
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Controlling HBV replication in vivo by intravenous administration of triggered PEGylated siRNA-nanoparticles.
    Carmona S; Jorgensen MR; Kolli S; Crowther C; Salazar FH; Marion PL; Fujino M; Natori Y; Thanou M; Arbuthnot P; Miller AD
    Mol Pharm; 2009; 6(3):706-17. PubMed ID: 19159285
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A single-monomer derived linear-like PEI-co-PEG for siRNA delivery and silencing.
    Tsai LR; Chen MH; Chien CT; Chen MK; Lin FS; Lin KM; Hwu YK; Yang CS; Lin SY
    Biomaterials; 2011 May; 32(14):3647-53. PubMed ID: 21324524
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effective siRNA delivery and target mRNA degradation using an amphipathic peptide to facilitate pH-dependent endosomal escape.
    Bartz R; Fan H; Zhang J; Innocent N; Cherrin C; Beck SC; Pei Y; Momose A; Jadhav V; Tellers DM; Meng F; Crocker LS; Sepp-Lorenzino L; Barnett SF
    Biochem J; 2011 Apr; 435(2):475-87. PubMed ID: 21265735
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The systemic delivery of siRNAs by a cell penetrating peptide, low molecular weight protamine.
    Choi YS; Lee JY; Suh JS; Kwon YM; Lee SJ; Chung JK; Lee DS; Yang VC; Chung CP; Park YJ
    Biomaterials; 2010 Feb; 31(6):1429-43. PubMed ID: 19954842
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficient siRNA delivery based on PEGylated and partially quaternized polyamine nanogels: enhanced gene silencing activity by the cooperative effect of tertiary and quaternary amino groups in the core.
    Tamura A; Oishi M; Nagasaki Y
    J Control Release; 2010 Sep; 146(3):378-87. PubMed ID: 20621664
    [TBL] [Abstract][Full Text] [Related]  

  • 39. RNA interference in the mouse vascular endothelium by systemic administration of siRNA-lipoplexes for cancer therapy.
    Santel A; Aleku M; Keil O; Endruschat J; Esche V; Durieux B; Löffler K; Fechtner M; Röhl T; Fisch G; Dames S; Arnold W; Giese K; Klippel A; Kaufmann J
    Gene Ther; 2006 Sep; 13(18):1360-70. PubMed ID: 16625242
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pancreatic cancer therapy by systemic administration of VEGF siRNA contained in calcium phosphate/charge-conversional polymer hybrid nanoparticles.
    Pittella F; Miyata K; Maeda Y; Suma T; Watanabe S; Chen Q; Christie RJ; Osada K; Nishiyama N; Kataoka K
    J Control Release; 2012 Aug; 161(3):868-74. PubMed ID: 22580114
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.